Last reviewed · How we verify
Ibuprofen 400 mg
Ibuprofen 400 mg, marketed by ASST Fatebenefratelli Sacco, is a well-established over-the-counter pain reliever and anti-inflammatory medication. The key composition patent expires in 2028, providing a significant period of market exclusivity. The primary risk is the potential increase in generic competition following the patent expiry.
At a glance
| Generic name | Ibuprofen 400 mg |
|---|---|
| Also known as | Ibuprofen-Sandoz, Advil, Motrin, Nsaid, Ibuprofen 400 mg Tablets BP |
| Sponsor | ASST Fatebenefratelli Sacco |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD) (NA)
- ERAS (Enhanced Recovery After Surgery) and Multimodal Analgesia in Laparoscopic Cholecystectomy
- Open-Label Placebo for Non-Specific Pain in the ED (NA)
- "Effect of Ibuprofen on Acute Inflammatory Response After One-Stage Periodontal Therapy" (PHASE4)
- Selected Exercise Program on Upper Cross Syndrome Post-unilateral Mastectomy (NA)
- Preemptive IV Ibuprofen for Neurocognitive Recovery and Analgesic Needs After Inguinal Hernia Surgery (PHASE4)
- Helping Osteoarthritis Patients to Walk With NSAID (PHASE4)
- Postoperative Analgesic Efficacy of SPSIPB in Anterior Cervical Discectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ibuprofen 400 mg CI brief — competitive landscape report
- Ibuprofen 400 mg updates RSS · CI watch RSS
- ASST Fatebenefratelli Sacco portfolio CI